Search results


Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
You searched for:
Results: 86
1

Respiratory

Chiesi has been developing medicines to treat respiratory disease for more than 30 years, in area of Slovakia from 2005. Thanks to modern treatments, patients with asthma or chronic obstructive pulmonary disease (COPD) are able to live more active lives with greater self-confidence. After all,...
2

Neonatology

By around the 37th week of pregnancy, babies will have developed to the point that they are able to survive outside the womb. Any child born before this point is referred to as premature. Thanks to the enormous progress in neonatology (Greek: “the study of newborns”), which is a branch...
3

Rare Diseases

The term “rare disease” applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point – in EU the threshold at 0.05% of the population, i.e. a disease affects less than 5 in 10,000 people in the EU; in the EU the number is estimated...
4

Transplantations

In cases where an essential organ fails and it is not possible to restore its function, a transplant often provides the only chance of survival. The progress made in transplant medicine and the improvement in the quality of life.  is not only due to improved surgical techniques but also to the...
5

Others

Chiesi, in order to provide quality treatment for a wide range of patients, also focuses on other areas including: Rheumatology - for patients suffering from rheumatic diseases, it has developed a medicine for the treatment of chronic pain. (Flamexin®) Infectology - frequent urological...
6

Home

-
7

Our company

Chiesi Slovakia s.r.o., a limited liability company, is a branch in 100 % ownership of Chiesi Pharmaceuticals GmbH, Vienna, which belongs to the Italian pharmaceutical company Chiesi Farmaceutici S.p.A., Parma. The portfolio of our mother company consists of products developed by its own...
8

History

Chiesi symbolizes success since 1935   Highlights from the Chiesi Group with focus on Chiesi Slovakia 1935 Giacomo Chiesi, the founder of Chiesi Farmaceutici, always aspired to have a laboratory to carry out research. Chiesi buys the “Pharma Biologica –...
9

Research & Development

Being able to offer innovative treatment options and thus improve the health and lives of our patients is the main power that drives us. Research and development area (R&D) is important to Chiesi not only as a technological focus company but for manufacturer of pharmaceuticals. The path from an...
10

Therapeutic Areas

-
11

Media Contact

Chiesi Slovakia s.r.o. Kovová 24 821 06 Bratislava   PharmDr. Martin Višňanský, MBA, PhD, MSc General Manager Chiesi Slovakia s.r.o. m.visnansky@chiesi.com Mobil: 00421-907-880-953 Tel.: 00421-2-59-30-00-60
12

Management

-
13

Job Opportunities

It is the people that make a company what it is and define what it can do. Our employees are critical factors in the success of this company. Our team is characterized by personal commitment, experience and clear identification with the Group’s corporate values.   Although we currently...
14

People at the Centre

Chiesi Group has around 4,800 employees worldwide, around 12 people are working for Chiesi Slovakia. They are highly qualified and entrepreneurial and thus contribute to continued growth of the company. Trust and a respectful and appreciative conduct shape our everyday work. All employees are...
15

Events

2020 January European Data Protection Day   February Cancer Day World Sick Day International Day of Expectations Possible   March International Day of Invalidity              World Healthy Sleep...
16

Contacts

The following contact details must to be used for comments or questions concerning our Company and cannot be used to report adverse event to our products or for medical questions. For this kind of reporting, please  refer to PHARMACOVIGILANCE
17

Sitemap

-
18

Pharmacovigilance

Chiesi has a system of pharmacovigilance to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate action when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicines is continually evaluated. When...
19

Legal Information

Name: Chiesi Slovakia s.r.o. Managing Director: PharmDr. Martin Višňanský, MBA, PhD. Principal Office: Kovová 24, 821 06 Bratislava, Slovensko Tel.: +421 2 59 30 00 60 Email: office.sk(at)chiesi.com http: www.chiesi.sk Co. Reg. No.: 35871105 VAT...
20

Data privacy/cookies

Act no. 18/2018 Z. z. on the Protection of Personal Data and on Amendments to Some Acts published in the Collection of Laws of the Slovak Republic Data privacy statement We are pleasant about you have visited our website. We respect the privacy of anyone who visits this website. Chiesi Slovakia...
21

Products

For more detailed product information, read the Package leaflet - Information for the user or the Summary of Product Characteristics (available at http://www.sukl.sk/  or https://www.adc.sk/ )
22

Search Result

-
23

News and Press-release

-
24

Chiesi Foundation

Founded in 2005, the Chiesi Foundation Onlus is a no-profit organisation which seeks to capitalise on Chiesi’s legacy of knowledge in order to promote health and alleviate the suffering of patients affected by chronic respiratory diseases, rare diseases and neonatal diseases. The Chiesi...
25

Disclaimer

Chiesi Slovakia s.r.o. has prepared the information contained on this website from various internal and external sources with due professional care. We take every reasonable effort to add to and update this information on a regular basis. The information contained on this website is intended only...
26

Ambulatory Care

Ambulatory Care
27

Hospital & Special Care

Hospital & Special Care
28

Anti-bribery Policy, Code of Ethics and Conduct and (Transparency Disclosures)

Code of Ethics & Compliance The Code of Ethics and Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature. The application of the following...
29

Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)

Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the maintenance treatment in adult patients with moderate to severe chronic...
30

World Day Against Cancer

-
31

World sick day

-
32

World Tuberculosis Day (WHO)

-
33

World renal day

-
34

World Autism Awareness Day

-
35

World Health Day (WHO)

-
36

XVI. Day of immunology in Martin

-
37

European Day for the rights of patients

-
38

World Asthma day

-
39

II.Congress SPFS & XXIV.Days of pneumo-pthyseology in Bardejov

-
40

ATS, San Diego

-
41

EAACI Munich

-
42

World No Tobacco Day

-
43

41st ECFC Beograde

-
44

World blood donor day

-
45

World Allergy Day

-
46

World humanitarian day

-
47

International Day for Cystic Fibrosis

-
48

28th International Congress of ERS, Paris

-
49

35. Congress of CZ/SK Alergo-immunology ČSAKI a SSAKI, Brno

-
50

World Day of Osteoporosis

-
51

7th EAPS , Paris

-
52

World COPD Day

-
53

World Prematurity day

-
54

Christmas day of breathing, Bratislava

-
55

TRIBUTE study shows superiority of Chiesi’s Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1

Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow®) in a single pressurised metered dose inhaler (pMDI) for COPD patients. Trimbow met the primary endpoint showing superiority vs Ultibro® in reducing COPD...
56

Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe

Chiesi is the first pharmaceutical company to have demonstrated with randomized clinical trials, two of which published in The Lancet 1,2, the efficacy of the triple extrafine combination to prevent exacerbations, improve symptoms and quality of life. Trimbow is the first fixed triple...
57

Chiesi Group reports an increased turnover in 2016 and consolidates its global presence

Chiesi Group closes 2016 with a turnover of €1.571 million, up 7.0% on 2015 (+9.6% at a constant exchange rate). The international footprint of the Group continues to grow: 83% of turnover comes from the non-Italian market. Significant growth in the European affiliates, which have now...
58

Glybera▼ (alipogene tiparvovec) in Europe

Parma, 20 April 2017 - Chiesi Farmaceutici Spa (“Chiesi”) acknowledges that uniQure biopharma B.V (uniQure), have taken the decision to withdraw the ongoing application for the Marketing Authorization Renewal of Glybera, for which Chiesi holds commercialization rights for Europe and...
59

For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.

For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study. TRINITY is the first study to demonstrate the superiority of triple therapy with a fixed dose combination of...
60

GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps

GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps   Chiesi Farmaceutici welcomes the recently published GOLD report but identifies three key elements in the treatment recommendations, which deserve thorough evaluation and further revision: Limited evidence base...
61

Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics

Parma, Italy — November 21, 2016— Chiesi Farmaceutici Spa (“Chiesi”), announced today that it has signed a definitive agreement for the acquisition of Atopix Therapeutics Limited, a UK clinical stage biotechnology company developing novel treatments for...
62

The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma

Tuesday, November 8 -- The Italian Prime Minister Matteo Renzi, has today visited Chiesi Farmaceutici at the Research Center in Parma. The Prime Minister scheduled a meeting with Ugo di Francesco, Group CEO,  Paolo Chiesi, Vice President, Alessandro Chiesi, Region Europe Director and...
63

Chiesi Group Announces Establishment of New Global Rare Diseases Division

Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities,...
64

Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD

Market leader in respiratory innovation highlights potentially harmful1 consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI)...
65

We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035

Today all of the Group’s affiliates, employees, communities and company partners commit to building a sustainable future   Parma, September 25th 2019 – Chiesi Farmaceutici, an international group focussed on improving the quality of people’s lives (the Chiesi Group),...
66

Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON

Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. As per the agreement, Chiesi Group is in-licensing a product whose active principle is idebenone for the treatment of...
67

Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification

Certified B Corporations meet the highest standards of verified social and environmental performance, transparency and accountability. Chiesi Group receives the B Corp certification from B Lab, a leading global sustainability non-profit body, in recognition of its corporate sustainability...
68

Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)

Cary, N.C., June 12, 2018 – Chiesi USA (key-A-zee), a specialty pharmaceutical company based in Cary, N.C., and the Italian biotech Holostem Terapie Avanzate S.r.l., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an investigational product,...
69

Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)

The Marketing Authorisation has been granted under “exceptional circumstances” according to the EU legislation, which aim to enable treatment of extremely rare disorders for which traditional large-scale clinical studies are not feasible. Velmanase alfa has been investigated in 34...
70

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic

The Group commits €3 million for donations to support the ongoing emergency Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world Company also announces a €1 million investment in new measures to...
71

Foster® & Foster Nexthaler®

This fixed combination consists of an anti-inflammatory inhalative corticosteroid and a long-acting bronchodilatory beta-2-sympathomimetic drug. The product is available as pMDI and DPI, too. Due to the synergism of both agents and its fast onset of action, it is indicated in the treatment of...
72

Budiair®

In bronchial asthma and other long-term (chronic obstructive) diseases of the respiratory tract, when treatment with inhaled corticosteroids is essential, the Modulite technology ensures the optimized size of inhaled particles. This product is available in our market, as pMDI.
73

Atimos®

Formoterol is an inhalative long-acting beta-2-agonist which acts as a bronchodilator. It is indicated in patients with obstructive pulmonary disease.
74

Bramitob®

Tobramycin is an aminoglycoside antibiotic which is produced by Streptomyces tenebrarius and it is administered via inhalative route. The therapeutic indication is the management of chronic pulmonary infections caused by pseudomonas aeruginosa in patients with cystic fibrosis.
75

Quinsair®

Levofloxacin is an antibacterial agent of the class of fluoroquinolones. It is administered by inhalation through 28-day cycles. It is indicated for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.
76

Flamexin®

It is non-steroidal anti-inflammatory medicine for relief of some symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, such as swelling, stiffness and pain in the joints.
77

Monural®

Fosfomycin is a broad-spectrum antibiotic which is used as an oral single-shot therapy in the acute treatment in woman and prophylaxis of uncomplicated urinary tract infections.
78

Otobacid N®

This combination contains dexamethasone, an anti-inflammatory glucocorticoid, dibucaine (cinchocaine), a local anesthetic and long-acting chinoline derivative, and butanediol, a polyvalent alcohol with antiseptic properties. It is used in the therapy of inflammatory diseases of the ear...
79

Curosurf®

Our product is a natural surfactant for substituting a lack of endogenous surfactant and is administered via intratracheal instillation. It adheres to the alveoli and reduces the surface tension, thereby preventing atelectasis (ventilation deficiency in the lung). The insufficiency of surfactant...
80

Peyona®

Caffeine citrate is an orphan drug only for hospital use, indicated for the treatment of primary apnoea of premature newborns. It can be administered intravenusly or orally.
81

Holoclar®

Treatment with Holoclar® is intended for adult patients with moderate to severe unilateral or bilateral limbal stem cell deficiency (ophthalmology). The condition is the maintenance of the limbus from which a biopsy may be taken at least 1-2 mm2 undamaged limbal cells.
82

Pamitor®

Pamidronate is a biphosphonate and a potent inhibitor of osteoclastic bone resorption. Pamidronic acid is indicated for the treatment of conditions associated with increased osteoclast activity such as tumour-induced hypercalcaemia, tumour-induced osteolysis or Paget’s disease.
83

Sufentanil Chiesi

Sufentanil is a synthetic opioid analgesic drug. It is used either as analgesic component or as an anesthetic agent for the induction and maintenance of balanced anesthesia.
84

Xomolix®

Droperidol is a butyrophenone and antidopaminergic drug with an inhibiting effect on the alpha-receptors of the area postrema of the brain. It has a strong central antiemetic effect and is mainly used to treat postoperative nausea and vomiting.
85

Kengrexal®

Cangrelor is a direct P2Y12 platelet receptor antagonist administered parenterally during intervention. Co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with undergoing percutaneous coronary intervention (PCI).
86

Trimbow®

The fixed triple-combination is intended for the treatment of advanced COPD. It contains anti-inflammatory inhaled corticosteroid and two substances from the group of bronchodilators: β-2 sympathomimetic and antimuscarinic bronchodilator. It is available in spray (pMDI) form; the spray...